Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Industry, Sector and Symbol:
Capitalization:- Market Cap: $1.54461 billion
- Outstanding Shares: 41,211,000
Average Prices:- 50 Day Moving Avg: $36.27
- 200 Day Moving Avg: $32.70
- 52 Week Range: $24.47 - $38.74
P/E:- Trailing P/E Ratio: 23.96
- Foreward P/E Ratio: 17.50
- P/E Growth: 1.48
Sales & Book Value:- Annual Revenue: $512.21 million
- Price / Sales: 3.03
- Book Value: $15.10 per share
- Price / Book: 2.49
Profitability:- EBIDTA: $159.99 million
- Net Margins: 13.42%
- Return on Equity: 14.50%
- Return on Assets: 9.00%
Debt:- Debt-to-Equity Ratio: 0.40%
- Current Ratio: 6.99%
- Quick Ratio: 6.02%
Misc:- Average Volume: 285,075 shs.
- Beta: 1.23
- Short Ratio: 8.43
Frequently Asked Questions for Emergent Biosolutions (NYSE:EBS)
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions, Inc. (NYSE:EBS) posted its earnings results on Thursday, August, 3rd. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.26 by $0.13. The company earned $100.77 million during the quarter, compared to analysts' expectations of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. Emergent Biosolutions's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.05) EPS. View Emergent Biosolutions' Earnings History.
When will Emergent Biosolutions make its next earnings announcement?
Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?
3 equities research analysts have issued 12-month price targets for Emergent Biosolutions' shares. Their forecasts range from $41.00 to $47.00. On average, they expect Emergent Biosolutions' stock price to reach $44.00 in the next year. View Analyst Ratings for Emergent Biosolutions.
What are analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
- 1. According to Zacks Investment Research, "Emergent reported lower-than-expected earnings in the second-quarter of 2017, with revenue missing estimates. The company’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. We are also positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it is expected to result in a reduced cost structure. On the flip side, the company’s sole dependence on BioThrax for its revenue is concerning. Meanwhile, Emergent faces competition from a number of companies with Biodefense products. Shares of the company have underperformed the broader industry so far this year. However, the U.S. government is the primary purchaser of BioThrax which is a big boost to the company." (8/11/2017)
- 2. Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Akcea Therapeut (AKCA), Impax Laboratories (IPXL), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT) and Tetraphase Pharmaceuticals (TTPH).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Fuad El-Hibri, Executive Chairman of the Board
- Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director
- Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer
- Adam Havey, Executive Vice President - Business Operations
- Ronald B. Richard, Lead Independent Director
- Sue Bailey M.D., Independent Director
- Zsolt Harsanyi Ph.D., Independent Director
- Jerome M. Hauer, Independent Director
- George A. Joulwan USA, Independent Director
Who owns Emergent Biosolutions stock?
Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.67%), Dimensional Fund Advisors LP (5.38%), Aberdeen Asset Management PLC UK (4.24%), State Street Corp (3.34%), Acadian Asset Management LLC (3.02%) and Royal Bank of Canada (2.33%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?
Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Acadian Asset Management LLC, Kennedy Capital Management Inc., State Street Corp, FIL Ltd, FMR LLC and GSA Capital Partners LLP. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Jerome M Hauer, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.
Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?
Emergent Biosolutions' stock was purchased by a variety of institutional investors in the last quarter, including Northern Trust Corp, Dimensional Fund Advisors LP, Rice Hall James & Associates LLC, Aberdeen Asset Management PLC UK, Renaissance Technologies LLC, New Amsterdam Partners LLC NY, Ameriprise Financial Inc. and Alliancebernstein L.P.. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy Emergent Biosolutions stock?
Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of Emergent Biosolutions stock can currently be purchased for approximately $37.62.
MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Emergent Biosolutions (NYSE:EBS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $44.00 (16.96% upside) |
Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/30/2017 | Chardan Capital | Reiterated Rating | Buy | $47.00 | N/A |  |
| 1/9/2017 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 10/1/2016 | Wells Fargo & Company | Set Price Target | Buy | $41.00 | N/A | |
| 8/5/2016 | J P Morgan Chase & Co | Lower Price Target | Overweight | $45.00 -> $36.00 | N/A | |
| 6/28/2016 | Singular Research | Lower Price Target | Buy | $44.00 -> $40.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Emergent Biosolutions (NYSE:EBS)Earnings History by Quarter for Emergent Biosolutions (NYSE EBS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | $0.41 | | | | | N/A | |
| 8/3/2017 | Q2 2017 | $0.26 | $0.13 | $111.57 million | $100.77 million | View | Listen | |
| 5/4/2017 | Q1 2017 | $0.31 | $0.23 | $121.30 million | $116.90 million | View | Listen | |
| 2/23/2017 | Q4 2016 | $0.48 | $0.74 | $120.45 million | $151.66 million | View | Listen | |
| 11/7/2016 | Q3 | $0.26 | $0.58 | $112.30 million | $142.91 million | View | Listen | |
| 8/4/2016 | Q2 | ($0.17) | ($0.18) | $111.20 million | $101.49 million | View | Listen | |
| 5/5/2016 | Q1 | ($0.07) | $0.16 | $101.83 million | $111.00 million | View | Listen | |
| 2/25/2016 | Q4 | $0.69 | $0.78 | $168.07 million | $168.10 million | View | Listen | |
| 11/5/2015 | Q315 | $0.55 | $0.83 | $151.42 million | $164.90 million | View | Listen | |
| 8/6/2015 | Q215 | $0.18 | $0.36 | $114.25 million | $126.10 million | View | Listen | |
| 5/7/2015 | Q1 | ($0.46) | ($0.50) | $62.70 million | $63.60 million | View | Listen | |
| 3/5/2015 | Q115 | $0.97 | $0.75 | $147.00 million | $148.00 million | View | Listen | |
| 11/6/2014 | Q414 | $0.37 | $0.67 | $126.90 million | $138.00 million | View | Listen | |
| 8/7/2014 | Q214 | $0.26 | $0.24 | $109.25 million | $110.30 million | View | Listen | |
| 5/8/2014 | Q114 | ($0.34) | ($0.40) | $57.30 million | $53.90 million | View | Listen | |
| 3/6/2014 | Q413 | $0.36 | $0.42 | $93.83 million | $94.10 million | View | Listen | |
| 11/7/2013 | Q313 | $0.21 | $0.37 | $79.13 million | $89.10 million | View | Listen | |
| 8/5/2013 | Q2 2013 | $0.21 | $0.29 | $75.73 million | $82.40 million | View | Listen | |
| 5/2/2013 | Q1 2013 | ($0.14) | ($0.22) | $46.17 million | $43.10 million | View | Listen | |
| 3/7/2013 | Q4 2012 | $0.44 | $0.44 | $95.09 million | $94.61 million | View | Listen | |
| 11/1/2012 | Q312 | $0.22 | $0.18 | $73.53 million | $66.60 million | View | N/A | |
| 8/2/2012 | | $0.21 | $0.21 | | | View | N/A | |
| 5/3/2012 | | ($0.18) | ($0.19) | | | View | N/A | |
| 3/8/2012 | | $0.72 | $0.78 | | | View | N/A | |
| 11/3/2011 | | ($0.04) | $0.04 | | | View | N/A | |
| 8/4/2011 | | $0.33 | $0.40 | | | View | N/A | |
| 5/5/2011 | | ($0.52) | ($0.64) | | | View | N/A | |
| 3/10/2011 | | $0.67 | $0.76 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Emergent Biosolutions (NYSE:EBS)Current Year EPS Consensus Estimate: $1.48 EPS
Next Year EPS Consensus Estimate: $2.15 EPS
Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Emergent Biosolutions (NYSE:EBS)Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 85.35%
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/14/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $38.50 | $962,500.00 | |
| 9/8/2017 | Adam Havey | EVP | Sell | 7,885 | $37.06 | $292,218.10 | |
| 9/7/2017 | Fuad El-Hibri | Chairman | Sell | 16,439 | $37.50 | $616,462.50 | |
| 9/5/2017 | Fuad El-Hibri | Chairman | Sell | 3,100 | $37.50 | $116,250.00 | |
| 8/31/2017 | Daniel Abdun-Nabi | CEO | Sell | 15,000 | $37.21 | $558,150.00 | |
| 8/31/2017 | Fuad El-Hibri | Chairman | Sell | 5,461 | $37.50 | $204,787.50 | |
| 8/15/2017 | Jerome M Hauer | Director | Sell | 10,776 | $35.83 | $386,104.08 | |
| 7/27/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $36.50 | $912,500.00 | |
| 7/20/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $35.50 | $887,500.00 | |
| 4/3/2017 | Adam Havey | EVP | Sell | 11,419 | $28.62 | $326,811.78 | |
| 3/8/2017 | Jerome M Hauer | Director | Sell | 2,576 | $31.27 | $80,551.52 | |
| 1/17/2017 | Adam Havey | EVP | Sell | 8,438 | $29.75 | $251,030.50 | |
| 1/17/2017 | Sue Bailey | Director | Sell | 19,424 | $29.78 | $578,446.72 | |
| 1/10/2017 | Daniel Abdun-Nabi | Insider | Sell | 28,240 | $31.28 | $883,347.20 | |
| 12/13/2016 | Ronald Richard | Director | Sell | 5,900 | $34.09 | $201,131.00 | |
| 6/6/2016 | George A Joulwan | Director | Sell | 4,700 | $44.12 | $207,364.00 | |
| 6/1/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,699 | $43.74 | $380,494.26 | |
| 5/27/2016 | Fuad El-Hibri | Major Shareholder | Sell | 9,835 | $43.50 | $427,822.50 | |
| 5/26/2016 | Fuad El-Hibri | Major Shareholder | Sell | 39,759 | $43.13 | $1,714,805.67 | |
| 5/25/2016 | Fuad El-Hibri | Major Shareholder | Sell | 85,000 | $42.52 | $3,614,200.00 | |
| 5/25/2016 | Zsolt Harsanyi | Director | Sell | 27,867 | $42.33 | $1,179,610.11 | |
| 5/24/2016 | Fuad El-Hibri | Chairman | Sell | 20,000 | $42.26 | $845,200.00 | |
| 5/23/2016 | Fuad El-Hibri | Chairman | Sell | 45,000 | $42.62 | $1,917,900.00 | |
| 5/20/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,701 | $42.00 | $365,442.00 | |
| 5/19/2016 | Jerome M Hauer | Director | Sell | 3,134 | $41.22 | $129,183.48 | |
| 5/13/2016 | Louis W Sullivan | Director | Sell | 47,631 | $39.21 | $1,867,611.51 | |
| 5/12/2016 | Fuad El-Hibri | Major Shareholder | Sell | 25,000 | $38.71 | $967,750.00 | |
| 5/12/2016 | Jerome M Hauer | Director | Sell | 4,700 | $38.50 | $180,950.00 | |
| 5/11/2016 | Louis W Sullivan | Director | Sell | 9,969 | $39.25 | $391,283.25 | |
| 4/22/2016 | Fuad El-Hibri | Major Shareholder | Sell | 4,209 | $40.50 | $170,464.50 | |
| 4/18/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,702 | $40.17 | $349,559.34 | |
| 4/18/2016 | Fuad El-Hibri | Major Shareholder | Sell | 20,791 | $40.50 | $842,035.50 | |
| 4/6/2016 | Fuad El-Hibri | Major Shareholder | Sell | 50,000 | $39.00 | $1,950,000.00 | |
| 4/6/2016 | Robert Kramer | EVP | Sell | 21,786 | $38.90 | $847,475.40 | |
| 4/4/2016 | Robert Kramer | EVP | Sell | 21,788 | $36.90 | $803,977.20 | |
| 4/1/2016 | Robert Kramer | EVP | Sell | 43,572 | $35.56 | $1,549,420.32 | |
| 3/14/2016 | Adam Havey | EVP | Sell | 4,359 | $33.96 | $148,031.64 | |
| 3/14/2016 | Jerome M Hauer | Director | Sell | 2,350 | $33.88 | $79,618.00 | |
| 3/11/2016 | Adam Havey | EVP | Sell | 11,112 | $33.84 | $376,030.08 | |
| 3/11/2016 | Louis W Sullivan | Director | Sell | 14,879 | $34.03 | $506,332.37 | |
| 3/7/2016 | Marvin L White | Director | Sell | 33,134 | $35.42 | $1,173,606.28 | |
| 1/4/2016 | Sue Bailey | Director | Sell | 11,520 | $38.79 | $446,860.80 | |
| 12/30/2015 | Ronald Richard | Director | Sell | 21,600 | $40.00 | $864,000.00 | |
| 12/24/2015 | Daniel Abdun-Nabi | CEO | Sell | 63,209 | $39.06 | $2,468,943.54 | |
| 11/19/2015 | Fuad El-Hibri | major shareholder | Sell | 17,871 | $37.50 | $670,162.50 | |
| 11/13/2015 | Fuad El-Hibri | major shareholder | Sell | 13,013 | $36.50 | $474,974.50 | |
| 11/12/2015 | Barry Labinger | EVP | Sell | 36,126 | $35.64 | $1,287,530.64 | |
| 11/9/2015 | Fuad El-Hibri | major shareholder | Sell | 13,225 | $35.50 | $469,487.50 | |
| 11/6/2015 | Fuad El-Hibri | major shareholder | Sell | 13,450 | $34.50 | $464,025.00 | |
| 11/3/2015 | Fuad El-Hibri | major shareholder | Sell | 13,689 | $33.50 | $458,581.50 | |
| 9/11/2015 | Sue Bailey | Director | Sell | 6,080 | $32.37 | $196,809.60 | |
| 8/13/2015 | George A Joulwan | Director | Sell | 7,200 | $34.72 | $249,984.00 | |
| 7/20/2015 | Fuad El-Hibri | Chairman | Sell | 234 | $34.50 | $8,073.00 | |
| 7/13/2015 | Ronald Richard | Director | Sell | 4,922 | $34.00 | $167,348.00 | |
| 6/29/2015 | Ronald Richard | Director | Sell | 4,923 | $32.76 | $161,277.48 | |
| 6/22/2015 | Fuad El-Hibri | Major Shareholder | Sell | 74,564 | $32.60 | $2,430,786.40 | |
| 6/16/2015 | Louis W Sullivan | Director | Sell | 13,457 | $31.33 | $421,607.81 | |
| 6/15/2015 | Adam Havey | EVP | Sell | 36,298 | $31.55 | $1,145,201.90 | |
| 6/15/2015 | Fuad El-Hibri | Major Shareholder | Sell | 45,436 | $32.18 | $1,462,130.48 | |
| 1/20/2015 | Fuad El-Hibri | Major Shareholder | Sell | 15,325 | $27.67 | $424,042.75 | |
| 12/26/2014 | Ronald Richard | Director | Sell | 5,000 | $28.00 | $140,000.00 | |
| 12/17/2014 | Ronald Richard | Director | Sell | 5,000 | $27.00 | $135,000.00 | |
| 12/11/2014 | Fuad El-Hibri | Major Shareholder | Sell | 119,341 | $26.00 | $3,102,866.00 | |
| 11/28/2014 | Fuad El-Hibri | Major Shareholder | Sell | 34,577 | $25.00 | $864,425.00 | |
| 11/25/2014 | Fuad El-Hibri | Major Shareholder | Sell | 9,014 | $25.00 | $225,350.00 | |
| 11/25/2014 | Zsolt Harsanyi | Director | Sell | 8,000 | $24.82 | $198,560.00 | |
| 11/12/2014 | Fuad El-Hibri | Major Shareholder | Sell | 2,311 | $25.00 | $57,775.00 | |
| 11/7/2014 | Robert Kramer | CFO | Sell | 2,625 | $24.00 | $63,000.00 | |
| 4/16/2014 | Robert Kramer | CFO | Sell | 50,189 | $24.34 | $1,221,600.26 | |
| 3/12/2014 | Adam Havey | EVP | Sell | 11,562 | $27.50 | $317,955.00 | |
| 3/11/2014 | Adam Havey | EVP | Sell | 17,655 | $26.96 | $475,978.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Emergent Biosolutions (NYSE:EBS)
Latest Headlines for Emergent Biosolutions (NYSE:EBS)
| Source: |
|
| Date | Headline |
|---|
 | Emergent BioSolutions (EBS) Secures $63M BARDA Contract to Develop Treatment for Cyanide Exposure - StreetInsider.com
www.streetinsider.com - September 20 at 4:16 AM |
 | Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure - GlobeNewswire (press release)
globenewswire.com - September 18 at 11:01 PM |
| Emergent BioSolutions (EBS) Secures $63M BARDA Contract to Develop Treatment for Cyanide Exposure
www.streetinsider.com - September 18 at 5:59 PM |
 | Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
finance.yahoo.com - September 18 at 5:59 PM |
 | Emergent Biosolutions (EBS) versus The Competition Head to Head Comparison
www.americanbankingnews.com - September 16 at 10:18 PM |
| Insider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 25,000 Shares of Stock
www.americanbankingnews.com - September 14 at 10:52 PM |
| Adam Havey Sells 7,885 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - September 12 at 4:14 PM |
 | Emergent BioSolutions (EBS) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 6:34 PM |
| Emergent Biosolutions, Inc. (EBS) Chairman Fuad El-Hibri Sells 16,439 Shares
www.americanbankingnews.com - September 8 at 4:22 PM |
| Fuad El-Hibri Sells 3,100 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - September 6 at 8:52 PM |
| Insider Selling: Emergent Biosolutions Inc (EBS) CEO Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 5 at 7:46 PM |
 | Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It ... - Nasdaq
www.nasdaq.com - September 4 at 10:50 PM |
| Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue? - Yahoo Finance
finance.yahoo.com - September 4 at 10:50 PM |
| Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue?
finance.yahoo.com - September 4 at 5:47 PM |
| Insider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 5,461 Shares of Stock
www.americanbankingnews.com - September 1 at 10:24 PM |
| Emergent Biosolutions (EBS) versus Theravance Biopharma (TBPHV) Head to Head Contrast
www.americanbankingnews.com - August 29 at 12:10 PM |
| Emergent Biosolutions, Inc. (EBS) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - August 25 at 9:44 PM |
| ETFs with exposure to Emergent BioSolutions, Inc. : August 23, 2017
finance.yahoo.com - August 23 at 8:24 PM |
| CVS Health (CVS) Releases Encouraging Flu Shot Survey Data - Nasdaq
www.nasdaq.com - August 22 at 3:46 AM |
| Insider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 10,776 Shares of Stock
www.americanbankingnews.com - August 17 at 7:58 PM |
| Biotech movers: Ionis Drops After GSK Bows Out of Partnership
finance.yahoo.com - August 11 at 6:34 PM |
| Emergent Biosolutions Inc (NYSE:EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 11 at 2:15 PM |
| Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 7:23 PM |
| See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
finance.yahoo.com - August 9 at 11:18 PM |
 | Emergent Biosolutions Inc Diversifies Its Revenue
www.fool.com - August 7 at 3:53 PM |
| Emergent Biosolutions, Inc. (EBS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 6 at 11:56 AM |
| Emergent Biosolutions, Inc. (EBS) Releases Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - August 5 at 5:32 PM |
| Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - August 5 at 4:25 AM |
| Edited Transcript of EBS earnings conference call or presentation 3-Aug-17 9:00pm GMT
finance.yahoo.com - August 4 at 6:21 PM |
| Erste CEO on Earnings, Czech Housing Market, Brexit
finance.yahoo.com - August 4 at 6:21 PM |
| Emergent Biosolutions misses 2Q profit forecasts
finance.yahoo.com - August 4 at 6:21 PM |
| Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
finance.yahoo.com - August 4 at 6:21 PM |
| Investor Network: Emergent BioSolutions Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 5:07 PM |
| Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
finance.yahoo.com - August 3 at 5:07 PM |
| ETFs with exposure to Emergent BioSolutions, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 6:46 PM |
| Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense
finance.yahoo.com - July 31 at 5:53 PM |
| Fuad El-Hibri Sells 25,000 Shares of Emergent Biosolutions, Inc. (NYSE:EBS) Stock
www.americanbankingnews.com - July 28 at 4:32 PM |
| Emergent BioSolutions (EBS) Secures Licensing Agreement with Valneva SE for Worldwide Exclusive Rights to Zika Vaccine Technology
www.streetinsider.com - July 27 at 12:16 AM |
| Emergent BioSolutions (EBS) Secures Licensing Agreement with Valneva SE for Worldwide Exclusive Rights to Zika ... - StreetInsider.com
www.streetinsider.com - July 26 at 6:41 PM |
| Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology
finance.yahoo.com - July 26 at 6:41 PM |
| VALNEVA and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
finance.yahoo.com - July 26 at 6:40 PM |
| Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri Sells 25,000 Shares
www.americanbankingnews.com - July 21 at 7:28 PM |
| Emergent Biosolutions, Inc. (NYSE:EBS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 21 at 11:42 AM |
| Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 3:25 PM |
| Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
finance.yahoo.com - July 20 at 3:25 PM |
| Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
finance.yahoo.com - July 19 at 9:18 PM |
 | Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
www.zacks.com - July 17 at 7:01 PM |
| Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
finance.yahoo.com - July 17 at 7:01 PM |
| Emergent Biosolutions, Inc. (EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:26 PM |
 | Emergent BioSolutions To Buy ACAM2000 Business From Sanofi For Up To $125 Mln
www.rttnews.com - July 16 at 5:28 PM |
Emergent Biosolutions (EBS) Chart for Thursday, September, 21, 2017
